Frankfurt:EB51

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%

Retrieved on: 
星期一, 三月 18, 2024
Cloud, Research, SKQ1, Quality control, Weather, NMPA, Therapeutic Goods Administration, Environment, Best, Intelligence, Patent, Patient, Conditional sentence, Ophthalmology, Hospital, POCT, Acquisition, CMC, European Medicines Agency, GMP, City, QMS, Bevacizumab, Chemistry, Yoy, US FDA, Traction, Good, Therapy, Point-of-care testing, VISTA, Pharmaceutical industry

The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.

Key Points: 
  • The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.
  • As of 31 December 2023, the Group had cash and cash equivalents of approximately HK$509.8 million (2022: approximately HK$543.5 million).
  • Together with the interim dividend of HK$0.045 per ordinary share paid on 13 September 2023, the total dividend for 2023 would be HK$0.09 (2022: HK$0.065) per ordinary share.
  • The Group's turnover is primarily made up of the ophthalmology segment ("Ophthalmology") and surgical (wound care and healing) segment ("Surgical").

Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%

Retrieved on: 
星期三, 八月 16, 2023
Ranibizumab, Therapy, Czech Republic, SkQ, CMC, COVID-19, Clinical trial, Therapeutic Goods Administration, Research, Diabetic retinopathy, Trial of the century, Chemistry, Bevacizumab, Telecanthus, Hospital, Traction, Trust, Acquisition, Patent, Investment, Patient, VISTA, European Medicines Agency, Macular edema, Growth, City, Conditional sentence, FDA, NMPA, US FDA, Disease, Safety, D, Pharmaceutical industry, PRC, Ophthalmology

HONG KONG, Aug 16, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").

Key Points: 
  • HONG KONG, Aug 16, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").
  • The profit of the Group increased by 22.0% to approximately HK$170 million as compared to approximately HK$139.2 million for the same period last year.
  • As of 30 June 2023, the Group had cash and cash equivalents of approximately HK$506 million (31 December 2022: approximately HK$543 million).
  • The Group's revenue is primarily made up of the segments of Ophthalmology and Surgical (wound care and healing).

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

Retrieved on: 
星期三, 七月 26, 2023
Bevacizumab, IgG4-related ophthalmic disease, Clinical trial, Research, IVT, VEGF, Eye, Patient, European, Visual acuity, Death, KDR, Endothelium, Safety, Pharmaceutical industry, Vaccine, EU

This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).

Key Points: 
  • This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).
  • Part 2 was a single-arm, open-label, multicentre, phase II study and 20 patients (including 6 patients from part 1) were enrolled in this part.
  • As of now, the clinical trial applications of EB12-20145P (HLX04-O) had been approved in Singapore and other countries and regions.
  • EB12-20145P (HLX04-O) has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.